(19)
(11) EP 1 949 903 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
23.05.2012 Bulletin 2012/21

(45) Mention of the grant of the patent:
18.04.2012 Bulletin 2012/16

(21) Application number: 06830873.3

(22) Date of filing: 10.10.2006
(51) International Patent Classification (IPC): 
A61K 31/522(2006.01)
A61K 31/53(2006.01)
A61K 31/519(2006.01)
 A61K 31/498(2006.01)
A61K 31/42(2006.01)
A61K 31/4709(2006.01)
(86) International application number:
PCT/ES2006/000564
(87) International publication number:
WO 2007/045705 (26.04.2007 Gazette 2007/17)

(54)

SELECTIVE A2A RECEPTOR ANTAGONISTS FOR THE TREATMENT OF AURICULAR FIBRILLATION

SELEKTIVE A2A-REZEPTORANTAGONISTEN ZUR BEHANDLUNG VON VORHOFFLIMMERN

ANTAGONISTES SÉLECTIFS DU RECEPTEUR A2A POUR LE TRAITEMENT DE LA FIBRILLATION AURICULAIRE

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

(30) Priority: 14.10.2005 ES 200502545

(43) Date of publication of application:
30.07.2008 Bulletin 2008/31

(73) Proprietor: Proyecto de Biomedicina Cima, S.L.
31008 Pamplona - Navarra (ES)

(72) Inventors:
  • FRANCO FERNÁNDEZ, Rafael
    E-08028 Barcelona (ES)
  • CIRUELA ALFÉREZ, Francisco
    E-08328 Barcelona (ES)
  • LLUÍS BISET, Carmen
    E-08029 Barcelona (ES)
  • MÜLLER, Christa
    53113 Bonn (DE)
  • CINCA CUSCULLOLA, Joan
    E-08017 Barcelona (ES)
  • HOVE-MADSEN, Leif
    E-08391 Tiana (Barcelona) (ES)

(74) Representative: ABG Patentes, S.L. 
Avenida de Burgos 16D Edificio Euromor
28036 Madrid
28036 Madrid (ES)


(56) References cited: : 
EP-A1- 0 544 444
WO-A1-02/055524
US-A- 5 998 387
US-A1- 2004 192 698
 WO-A1-01/40245
US-A- 4 772 607
US-A1- 2003 022 890
   
  • BERTOLET B D ET AL: "Myocardial infarction related atrial fibrillation: role of endogenous adenosine" HEART, BMJ, LONDON, GB, vol. 78, 1 January 1997 (1997-01-01), pages 88-90, XP003014314 ISSN: 1355-6037
  • DATABASE BIOSIS [Online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; January 2002 (2002-01), KULISEVSKY JAIME ET AL: "A double-blind crossover, placebo-controlled study of the adenosine A2A antagonist theophylline in Parkinson's disease" XP002518252 Database accession no. PREV200200217042 & CLINICAL NEUROPHARMACOLOGY, vol. 25, no. 1, January 2002 (2002-01), pages 25-31, ISSN: 0362-5664
  • YASUI KOZO ET AL: "Theophylline induces neutrophil apoptosis through adenosine A2A receptor antagonism" JOURNAL OF LEUKOCYTE BIOLOGY, vol. 67, no. 4, April 2000 (2000-04), pages 529-535, XP002518251 ISSN: 0741-5400
  • BERTOLET B.D. ET AL.: 'Myocardial infarction related atrial fibrillation: role of endogenous adenosine' HEART vol. 78, 1997, pages 88 - 90, XP003014314
 
Remarks:
The file contains technical information submitted after the application was filed and not included in this specification
 
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).